Welcome to SANN
The Severe Asthma National Network (SANN) was established in 2010.
SANN is a UK multidisciplinary team of healthcare professionals dedicated to improving severe asthma care through collaboration, education, research and shared best practice. Our members include specialist nurses, physiotherapists, pharmacists, psychologists, clinicians and researchers from across the UK, working together to support best practice, education, research and shared learning around severe asthma care, including biologic therapies.
Each team member plays a key role in advancing clinical care, developing educational resources and facilitating national collaboration.
Our Aims:
Bringing together healthcare professionals to improve care for children, young people, and adults with severe asthma.
Sharing best practice to enhance clinical standards and patient outcomes.
Developing educational opportunities to support healthcare professionals in severe asthma care.
Influencing care delivery to improve severe asthma treatment pathways for all age groups.
Providing expert resources to support clinicians, researchers, and policymakers.
Driving research and audit to advance evidence-based asthma management.
Supporting national collaboration to strengthen severe asthma networks and professional partnerships.
News & Events
Our Team
Publications
M28 - Severe Asthma, Biological Therapy, and Homecare: A Review of National Practice
Holmes L, Clayton S (on behalf of SANN)
Thorax 2023;78:A277
A national snapshot of severe asthma services across the UK, exploring how biological therapies are initiated, monitored, and delivered. The study highlights strengths in alignment with national guidelines, while also identifying key gaps in pre-biologic counselling, homecare training, and follow-up consistency.
P4 - Omalizumab: A National Review of Practise Across the United Kingdom
Holmes L (on behalf of SANN)
Thorax 2012;67:A65
An audit of how Omalizumab is used across UK centres, revealing wide variation in how treatment is assessed, administered, and monitored. The findings underscore the need for national guidance to ensure consistent, evidence-based care for patients with severe allergic asthma.